[Cited FineTest ELISA Kit] Current Research on Liver Steatosis Treatment

FineTest ELISA kit contributes to the research on liver steatosis treatment. The immunoassay is designed to measure INSR-β level in serum.

Article Title: Metabolically and epigenetically reprogrammed splenic TRNP1^hiCD8⁺ T cells exacerbate liver fibrosis
Journal Title: Nature Genetics
DOI: 10.1038/s41588-026-02660-5
IF: 25.5
PMID: 42420523

Abstract: Metabolic dysfunction-associated steatotic liver disease (MASLD), especially its severe form, metabolic dysfunction-associated steatohepatitis (MASH), progresses to liver fibrosis, leading to cirrhosis and liver cancer. The cross-talk between spleen and liver in MASLD/MASH progression remains poorly understood. Here we found enlarged spleens in patients with MASLD and identified induced TRNP1hiCD8+ T cells in spleens of MASLD/MASH mouse models and patients. These cells exhibited pro-fibrotic properties through secretion of INSR-α. Mechanistically, demethylated DNA and H3K27me3, increased H3K27ac and bolstered enhancer-promoter contact synergistically reorganized chromatin topologically associating domains spatially to initiate the expression of transcription factor TRNP1 in splenic CD8+ T cells. TRNP1 then transcriptionally activated the expression of FURIN and CTSD, promoting the maturation and ectodomain shedding of INSR-α and facilitating its secretion to activate hepatic stellate cells. In vivo blockade of INSR-α using neutralizing antibodies alleviated MASLD/MASH-induced liver fibrosis. This study reveals splenic TRNP1hiCD8+ T cells with pro-fibrotic properties and suggests a potential anti-fibrotic strategy.

Keywords: Liver Steatosis Treatment, Epigenetics, Liver Fibrosis, Liver Cirrhosis, Metabolic Disorders, Chronic Liver Disease

Immunoassay

Validated Image

Figure Source: Nat Genet. 2026 Aug;58(8):1891-1905. doi: 10.1038/s41588-026-02660-5.